Specialized Research Khavinson Bioregulator

Vesilute

Also known as: Peptídeo da bexiga, Peptídeo urinário

Molecular Identifiers

Molecular Formula

C9H14N2O7

CAS Number

3918-84-1

PubChem CID

99716

UNII

38Y324JU2X

Molecular Weight

262.22 Da

Overview

Urinary tract bioregulatory dipeptide developed by the Khavinson group. Acts on the bladder epithelium, regulating gene expression and supporting bladder function. Marketed in Russian pharmacies as an oral capsule formulation for urological support in short cycles.

Vesilute is presented as a short urinary tract bioregulator acting on the bladder epithelium, with proposed normalization of gene expression in vesical tissue. The clinical effect described in the Russian literature is support for urinary function, particularly in lower urinary tract aging and mild functional complaints.

Outside Russia, Vesilute has no regulatory approval or recognized clinical indication. The product is marketed in Russian pharmacies as oral capsules (RLS registry), typically in short cycles of 20–30 days, repeated every 4–6 months. In other markets it is dispensed by compounding pharmacies as off-label use. The evidence base is predominantly Russian, with few independent human clinical trials.

Within the Khavinson family, Vesilute sits on the urogenital axis alongside Prostamax (prostate) and Testagen (testicular): each is proposed as a tissue-specific bioregulator of the urogenital apparatus, distinguished more by proposed target tissue than by overall mechanism. All of this comparative literature is largely Russian and preclinical.

Sequence (1 letter): ED
Extended notation: Glu-Asp

Half-life

~2-4 hours

Administration Route

Subcutaneous or intramuscular

Category

Specialized Research

Mechanism of Action

  • Regulation of gene expression in the bladder epithelium
  • Support for detrusor and trigone function
  • Modulation of urothelium cell renewal
  • Bioregulatory effect on the lower urinary tract
  • Protection of the bladder epithelium against age-related changes

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 1-2 capsules orally (0.2 g per capsule, containing AKS-M peptide complex)
Frequency 1-2 times daily, with meals
Timing With meals
Duration 20-30 days per cycle, repeat the course every 4-6 months

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Injection site pain
  • Local redness (rare)

Product Properties

Purity >95%
Appearance White lyophilized powder
Solubility Soluble in water and bacteriostatic water
Source Solid-phase peptide synthesis (SPPS)
Storage Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles.

Presentations & Preparation

Vials of Vesilute found in the research market:

10 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per vial
  • Inject the diluent slowly against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on Vesilute.

2021 · Molecules

Peptide regulation of gene expression - a systematic review

Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

Bronchogen

1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals

Cardiogen

Chonluten

1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals

Crystagen

1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals